Hanxue Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanxue Wu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Fanni Li
Department of Talent Highland, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication - Hongli Gao
Department of Physiology and Pathophysiology, School of Medicine, Xi’an Jiaotong University, Xi’an, China
1 shared publication - Jia-Wei Wang
Department of Physiology and Pathophysiology, School of Medicine, Xi’an Jiaotong University, Xi’an, China
1 shared publication - Jiaxi Xu
Department of Physiology and Pathophysiology, Xi’an Jiaotong University Health Science Center, Xi’an, China
1 shared publication - Qi Sun
Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an 710061, China.
1 shared publication - Rui Yang
Institute of Neuroscience, Translational Medicine Institute, Health Science Center, School of Basic Medical Sciences, Xi’an Jiaotong University
1 shared publication
Latest Publications
- 24 February 2022
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 22 (4) , 311-325
AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment
Hypertension is one of the most prevalent cardiovascular disorders worldwide, affecting 1.13 billion people, or 14% of the global population. Hypertension is the single biggest risk factor for cerebrovascular dysfunction. According to the American Heart Association, high blood pressure (BP), especially in middle-aged individuals (~ 40 to 60 years old), is associated with an increased risk of dementia, later in life. Alzheimer’s disease and cerebrovascular disease are the two leading causes of dementia, accounting for around 80% of the total cases and usually combining mixed pathologies from both. Little is known regarding how hypertension affects cognitive function, so the impact of its treatment on cognitive impairment has been difficult to assess. The brain renin-angiotensin system (RAS) is essential for BP regulation and overactivity of this system has been established to precede the development and maintenance of hypertension. Angiotensin II (Ang-II), the main peptide within this system, induces vasoconstriction and impairs neuro-vascular coupling by acting on brain Ang-II type 1 receptors (AT1R). In this review, we systemically analyzed the association between RAS and biological mechanisms of cognitive impairment, from the perspective of AT1R located in the central nervous system. Additionally, the possible contribution of brain AT1R to global cognition decline in COVID-19 cases will be discussed as well.
- 24 February 2022
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 22 (4) , 311-325
AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment
Hypertension is one of the most prevalent cardiovascular disorders worldwide, affecting 1.13 billion people, or 14% of the global population. Hypertension is the single biggest risk factor for cerebrovascular dysfunction. According to the American Heart Association, high blood pressure (BP), especially in middle-aged individuals (~ 40 to 60 years old), is associated with an increased risk of dementia, later in life. Alzheimer’s disease and cerebrovascular disease are the two leading causes of dementia, accounting for around 80% of the total cases and usually combining mixed pathologies from both. Little is known regarding how hypertension affects cognitive function, so the impact of its treatment on cognitive impairment has been difficult to assess. The brain renin-angiotensin system (RAS) is essential for BP regulation and overactivity of this system has been established to precede the development and maintenance of hypertension. Angiotensin II (Ang-II), the main peptide within this system, induces vasoconstriction and impairs neuro-vascular coupling by acting on brain Ang-II type 1 receptors (AT1R). In this review, we systemically analyzed the association between RAS and biological mechanisms of cognitive impairment, from the perspective of AT1R located in the central nervous system. Additionally, the possible contribution of brain AT1R to global cognition decline in COVID-19 cases will be discussed as well.